Designing Future Health by Selective Serine Protease Inhibition


SERPINx BV is a Dutch protein therapeutics company involved in developing novel designer serine protease inhibitor (serpin) therapeutics for hemostasis, inflammatory and complement system associated diseases. Our universal platform technology can be utilized for a variety of disease areas, including angioedema, thrombosis, colitis, hemophilia A and complement-driven disorders. 

It is our goal to transform excellent and promising research output into novel high-value state-of-the-art therapeutics to tackle unmet medical needs for patients.

 Our lead compound (SPx-001) reached preclinical proof-of-concept stage as a “first-in-class” therapeutic for Heriditary Angioedema (Type I, II & III), Colitis and Thrombosis.